ClearPoint Neuro Inc vs Cronos Group Inc — how do they compare? ClearPoint Neuro Inc trades at $14.86 (market cap $454.21M), while Cronos Group Inc trades at $3.08 (market cap $1.14B). The key difference: Cronos Group Inc is far larger — about 2.5× ClearPoint Neuro Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | CRON | |
|---|---|---|
Market Cap | $454.21M | $1.14B |
Sector | Health | Health |
52-Week High | $29.60 | $3.27 |
52-Week Low | $8.66 | $2.30 |
Enterprise Value | $488.79M | $341.13M |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →